These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26692431)

  • 21. [Critical analysis of controlled pharmacologic studies in obsessive compulsive disorder].
    Brochier T; Hantouche E
    Encephale; 1989; 15(3):325-33. PubMed ID: 8641159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obsessive-compulsive disorder in Tourette syndrome.
    Goodman WK; Storch EA; Geffken GR; Murphy TK
    J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.
    Fineberg NA; Reghunandanan S; Brown A; Pampaloni I
    Aust N Z J Psychiatry; 2013 Feb; 47(2):121-41. PubMed ID: 23125399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
    Szechtman H; Harvey BH; Woody EZ; Hoffman KL
    Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):453-66. PubMed ID: 21809258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating obsessive-compulsive disorder. Options include medication, psychotherapy, surgery, and deep brain stimulation.
    Harv Ment Health Lett; 2009 Mar; 25(9):4-5. PubMed ID: 19368037
    [No Abstract]   [Full Text] [Related]  

  • 33. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.
    Zai G; Brandl EJ; Müller DJ; Richter MA; Kennedy JL
    Pharmacogenomics; 2014 Jun; 15(8):1147-57. PubMed ID: 25084207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Resistance and refractoriness in obsessive-compulsive disorder].
    Ferrão YA; Diniz JB; Lopes AC; Shavitt RG; Greenberg B; Miguel E
    Braz J Psychiatry; 2007 Oct; 29 Suppl 2():S66-76. PubMed ID: 18172943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of obsessive-compulsive disorder.
    Ko SM
    Br J Clin Pract; 1995; 49(1):36-9. PubMed ID: 7742183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.
    Fineberg NA; Stein DJ; Premkumar P; Carey P; Sivakumaran T; Vythilingum B; Seedat S; Westenberg H; Denys D
    Int Clin Psychopharmacol; 2006 Nov; 21(6):337-43. PubMed ID: 17012980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art].
    Kordon A; Zurowski B; Wahl K; Hohagen F
    Nervenarzt; 2011 Mar; 82(3):319-20, 322-4. PubMed ID: 21340636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.
    Denys D; Zohar J; Westenberg HG
    J Clin Psychiatry; 2004; 65 Suppl 14():11-7. PubMed ID: 15554783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.